J

Jounce Therapeutics Inc
F:21J

Watchlist Manager
Jounce Therapeutics Inc
F:21J
Watchlist
Price: 1.71 EUR Market Closed
Market Cap: 89.2m EUR

Net Margin
Jounce Therapeutics Inc

-62.1%
Current
-69%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-62.1%
=
Net Income
-50.9m
/
Revenue
82m

Net Margin Across Competitors

No Stocks Found

Jounce Therapeutics Inc
Glance View

Market Cap
88.4m EUR
Industry
Biotechnology

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2017-01-26. The firm is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. The firm has developed a suite of integrated technologies that consist of its Translational Science Platform, enabling it to interrogate the cellular and molecular composition of tumors. Its program, JTX-8064, is a humanized IgG4, anti-LILRB2 monoclonal antibody designed to reprogram macrophages. JTX-8064 is being developed for patients with either PD-(L)1-inhibitor resistant or PD-(L)1 inhibitor-sensitive tumors. Vopratelimab is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS). Pimivalimab is a clinical-stage anti-PD-1 monoclonal antibody that is being developed primarily for its use in combination with its product candidates.

21J Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-62.1%
=
Net Income
-50.9m
/
Revenue
82m
What is the Net Margin of Jounce Therapeutics Inc?

Based on Jounce Therapeutics Inc's most recent financial statements, the company has Net Margin of -62.1%.

Back to Top